Cost-effectiveness of oral antiplatelet agents--current and future perspectives. - Wikidata - wikimedia - TriplyDB

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

http://www.wikidata.org/entity/Q37913974

about

Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.Cost-effectiveness of heart failure therapies.

P2860

Q36754513-8A8A053B-26CE-48BC-99BC-CA7BB0FA4A3D Q38128171-5B1201F5-1CE2-4209-9BD2-84FC3E0AFDA4 Q45897479-9E2779BF-4768-4613-97FE-5BCA21D6E7CE

P2860

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

http://www.wikidata.org/entity/Q37913974

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

@en

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

@nl

type

label

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

@en

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

@nl

prefLabel

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

@en

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

@nl

P1433

Q37913974-6FF558F5-20BE-488B-9CD0-31D568C69847

P1476

Q37913974-19340666-1410-4B75-A071-482FEFEE6A70

P2093

Q37913974-42C466B5-902E-4532-BAB0-71EBCA0CA4EE

Q37913974-5C4710FF-FC26-4E5C-811D-91AD638AEDB4

Q37913974-EE991F11-08E2-4BC1-AAA4-DDA4B79A97FE

P2860

Q37913974-01F78F2E-6FAE-4153-9496-A4254A4DD341

Q37913974-132C732D-A0E2-4359-87DB-FA0083B2A7ED

Q37913974-13FDFD82-C248-4498-A0E0-CF8CEF2889CE

Q37913974-1DE6D85F-9D1D-46D2-9483-4ABFCFF29DA8

Q37913974-2016DBA5-7552-4683-8C7B-D9D65E08C35C

Q37913974-25C8B499-BFF9-4A4D-BDF1-DDB353BA21D7

Q37913974-2ECE56C4-94A1-49F6-8950-5C8A4F947E56

Q37913974-30203C9A-7FAC-4A4D-8610-82E13007BF42

Q37913974-325A8A1A-B127-4BD4-82E6-E3044CFF23E3

Q37913974-38FAE4AD-C4FA-4DCA-B213-72E44F05049C

P304

Q37913974-77AF1990-0391-4EC3-A7F6-E24EBF00756E

P31

Q37913974-57A2CEDA-3E84-45CC-9014-53CE1FCFD52C

P356

Q37913974-B35AFCC7-AF42-439E-9FA3-7A666B74C16A

P407

Q37913974-FCB03196-444F-42ED-9EC0-F9C266C4E551

P433

Q37913974-29EBAB3C-83FD-4BF5-A855-6DFEC5ED2A15

P478

Q37913974-E0D33FF7-8D16-4AD1-A967-4EDA5062A9CE

P577

Q37913974-36D35B6F-BA77-42C4-85E5-A653B563F713

P698

Q37913974-E9CBB35D-0948-48DD-AA8B-FEF67D44167D

P356

NRCARDIO.2011.119

P1433

Nature Reviews Cardiology

P1476

Cost-effectiveness of oral antiplatelet agents--current and future perspectives.

@en

P2093

David J Cohen

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Magnuson

http://www.w3.org/2001/XMLSchema#string

Suzanne V Arnold

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study

Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

P304

580-591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCARDIO.2011.119

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21826073

http://www.w3.org/2001/XMLSchema#string